| ID | 66161 |
| JaLCDOI | |
| FullText URL | |
| Author |
Minami, Daisuke
Department of Internal Medicine, Hosoya Hospital
Hosoya, Takeshi
Department of Internal Medicine, Hosoya Hospital
Hosoya, Masaharu
Department of Internal Medicine, Hosoya Hospital
Nagano, Akichika
Department of Respiratory Medicine, Himeji Saint Mary’s Hospital
Nakajima, Yasuhiro
Department of Respiratory Medicine, Himeji Saint Mary’s Hospital
Miyahara, Nobuaki
Department of Internal Medicine, Himeji Saint Mary’s Hospital
Kanehiro, Arihiko
Department of Internal Medicine, Himeji Saint Mary’s Hospital
|
| Abstract | A 74-year-old Japanese woman presented with a 45-year history of refractory asthma. She had been treated with inhaled corticosteroids, a long-acting β2-agonist, and a long-acting muscarinic antagonist for 6 months. She also had a repeated viral infection. Her condition had been characterized as a refractory asthma associated with type 2 and non-type 2 traits. We began treatment with tezepelumab. The control of the patient’s asthma symptoms and quality of life improved greatly within 1 month (changes in eosinophil count from 748 to 96 /μL, in FeNO from 32 to 17 ppb, in the Asthma Quality of Life Questionnaire score from 3.59 to 6.68, and in the Asthma Control Test score from 13 to 23). Tezepelumab was effective as an initial biologic agent for a patient with refractory asthma associated with type 2 and non-type 2 traits.
|
| Keywords | tezepelumab
biologic agent
eosinophilic
non-type 2
severe asthma
|
| Amo Type | Case Report
|
| Publication Title |
Acta Medica Okayama
|
| Published Date | 2023-12
|
| Volume | volume77
|
| Issue | issue6
|
| Publisher | Okayama University Medical School
|
| Start Page | 671
|
| End Page | 674
|
| ISSN | 0386-300X
|
| NCID | AA00508441
|
| Content Type |
Journal Article
|
| language |
English
|
| Copyright Holders | Copyright Ⓒ 2023 by Okayama University Medical School
|
| File Version | publisher
|
| Refereed |
True
|
| PubMed ID | |
| Web of Science KeyUT |
